Table 2.
Description of HBV and HCV LP patients (N = 2290), categorised by ALD/LSLD in 11 Spanish hospitals.
| Overall | HBV (N = 505) | HCV (N = 1785) | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Late presentation to carea | |||
| Yes | 588 (25.7) | 78 (15.4) | 510 (28.6) |
| Advanced liver disease | 552 (24.1) | 72 (14.3) | 480 (26.9) |
| Missing values | 10 (0.4) | 2 (0.4) | 8 (0.5) |
| Fibrosis stage | |||
| F3 | 170 (7.4) | 17 (3.4) | 153 (8.6) |
| F4 | 359 (15.7) | 48 (9.5) | 311 (17.4) |
| APRI > 1.5 | 23 (1.0) | 7 (1.4) | 16 (0.9) |
| Late-stage liver disease | 122 (5.3) | 28 (5.5) | 94 (5.2) |
| Hepatocellular carcinoma | 55 (2.4) | 10 (2.0) | 45 (2.5) |
| Missing values | 78 (3.4) | 0 (0) | 78 (4.3) |
| Decompensated cirrhosis defining liver complicationsb | |||
| Yes | 75 (3.3) | 19 (3.8) | 56 (3.1) |
| Jaundice | 21 (0.9) | 9 (1.8) | 12 (0.7) |
| Hepatic encephalopathy | 8 (0.3) | 0 (0) | 8 (0.4) |
| Ascites | 37 (1.6) | 11 (2.1) | 26 (1.4) |
| Variceal bleeding | 18 (0.8) | 3 (0) | 15 (0.8) |
| Missing values | 214 (9.3) | 133 (26.3) | 186 (10.4) |
ALD advanced liver disease, APRI aspartate aminotransferase to platelet ratio, F3 stage 3 fibrosis, F4 stage 4 fibrosis, HBV hepatitis B virus, HCV hepatitis C virus, LP late presentation, LSLD late-stage liver disease.
aLate presentation to care includes those with ALD and LSLD, of which, some patients may classify in both categories (i.e. a patient may have fibrosis F4 and a liver complication).
bNumber of patients for each type of liver complication sum to more than the “YES” total because some patients reported more than one liver complication.